German Accelerator Life Sciences (GALS) - Advise, Connect, Inspire

German Accelerator Life SciencesGerman Accelerator Life Sciences (GALS) helps young German life science companies succeed in the global market. GALS provides individualized and highly flexible services, tailored towards the specific needs and objectives of startups and emerging companies in the life sciences. Experienced mentors and consultants work with the participating teams to establish networks of potential clients, partners, and investors.

Applicants must be promising emerging life science companies that have great potential to benefit from the GALS program. Companies must have an affiliation with Germany, i.e. incorporated in Germany or with significant operations there. Applicants must develop a product or service in (at least) one of the five supported life science segments: Digital Health, Medical Devices, Diagnostics, Therapeutics, or Platform Technologies. The stage of the company's growth is relevant; the age of the company is not.

Application
The GALS application consists of around 20 questions about your company, team, technology, and business plan. It only takes a couple of hours to complete. We also request that companies submit additional materials with their application, such as a slide deck and a product demo (if available). Companies apply to the GALS program via the F6S platform.

GALS accepts companies into the program on a rolling basis. Companies can apply any time. Applications are reviewed by the Selection Committee every 6-8 weeks. Program start dates are flexible.

Next application deadline: March 31, 2017

The GALS Selection Committee meets approximately every 6-8 weeks to evaluate new applications. GALS then invites selected promising companies to an in-person workshop for a further assessment of their technology/approach and business strategy.

All services provided by GALS are free of charge for program participants, however GALS will not cover any related travel or living expenses.

For further infromation, please visit:
http://germanaccelerator.com/life-sciences/

About the German Accelerator Life Sciences
The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi), with the goal of helping German startups and young companies succeed in the global marketplace. GALS offers support in multiple areas, from free office space in the world's leading life science innovation hub, to mentoring and advising from industry experts and experienced leaders. GALS opened its doors in October 2015 and has its headquarters in Cambridge, Massachusetts.

Most Popular Now

Do Fitness Apps do More Harm than Good?

A study published in the British Journal of Health Psychology reveals the negative behavioral and psychological consequences of commercial fitness apps reported by users on social media. These impacts may...

AI Tool Beats Humans at Detecting Parasi…

Scientists at ARUP Laboratories have developed an artificial intelligence (AI) tool that detects intestinal parasites in stool samples more quickly and accurately than traditional methods, potentially transforming how labs diagnose...

Making Cancer Vaccines More Personal

In a new study, University of Arizona researchers created a model for cutaneous squamous cell carcinoma, a type of skin cancer, and identified two mutated tumor proteins, or neoantigens, that...

AI can Better Predict Future Risk for He…

A landmark study led by University' experts has shown that artificial intelligence can better predict how doctors should treat patients following a heart attack. The study, conducted by an international...

A New AI Model Improves the Prediction o…

Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the...

AI System Finds Crucial Clues for Diagno…

Doctors often must make critical decisions in minutes, relying on incomplete information. While electronic health records contain vast amounts of patient data, much of it remains difficult to interpret quickly...